Mercer elected DDDI Section Vice Chair and Selected for Elite Training Opportunity
Congratulations to Dr. Susan Mercer, assistant professor of pharmaceutical sciences, for being elected by her peers to serve the American Association of Pharmaceutical Scientists (AAPS) as the Drug Discovery and Development Interface (DDDI) Section vice chair. AAPS is a professional, scientific association of approximately 12,000 members employed in industry, academia, government and other research institutes worldwide. The DDDI Section focuses on issues at the critical interface between drug discovery and development and the effective transition of preclinical candidates into the clinical development phase. Mercer’s term of office took effect at the AAPS Annual Meeting and Exposition, in Chicago, Ill., in October 2012.
Dr. Susan Mercer has also been selected to attend the Training in Neurotherapeutics Discovery and Development for Academic Scientists Course supported by the National Institute of Neurological Disorders and Stroke and the National Institute of Health Blueprint for Neuroscience Research. She was one of 30 chosen to attend the course from more than 100 applicants.
This training program in neurotherapeutics discovery and development is an intensive three-and-a-half-day course that provides trainees with the various knowledge elements required to discover and advance a neurotherapeutic agent to an Investigational New Drug (IND) application. The course will also address the unique challenges inherent in developing treatments for nervous system disorders as well as the particular challenges that academic neuroscientists are likely to face in planning and conducting drug discovery research. Following the course, the training program will continue for a two-year period during which students will have individualized mentoring.
Some of the topics to be covered in the course include:
• Overview of the neurotherapeutics discovery and development process
• Generating lead compounds
• ADME, formulation and non-clinical proof-of-concept
• Preclinical proof-of-concept/target engagement studies
• Toxicology, IND enabling studies, preparation of the IND
• Experimental medicine and biomarkers
• Interacting with the FDA
• Intellectual property
• Funding academic drug discovery research